Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

sotera health topco inc - SHC

SHC

Close Chg Chg %
13.30 -0.35 -2.63%

Closed Market

12.95

-0.35 (2.63%)

Volume: 2.23M

Last Updated:

Nov 26, 2024, 4:00 PM EDT

Trade Now

Company Overview: sotera health topco inc - SHC

SHC Key Data

Open

$13.23

 Day Range

12.72 - 13.32

52 Week Range

10.71 - 17.44

 Market Cap

$3.77B

Shares Outstanding

283.24M

 Public Float

152.71M

Beta

2.08

 Rev. Per Employee

N/A

P/E Ratio

53.59

 EPS

$0.25

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.56M

  

SHC Performance

1 Week
 
 1.01%
 
1 Month
 
 -15.85%
 
3 Months
 
 -16.13%
 
1 Year
 
 -6.83%
 
5 Years
 
 N/A
 

SHC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 8
Full Ratings ➔

About sotera health topco inc - SHC

Sotera Health Co. provides mission-critical sterilization, lab testing and advisory services to the medical device and pharmaceutical industries. It also provides end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers. The firm operates through the following businesses: Sterigenics, Nordion, and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets by using following technologies: gamma irradiation, EO processing and E-beam irradiation. The Nordion business provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process. The Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was founded in 1978 and is headquartered in Broadview Heights, OH.

SHC At a Glance

Sotera Health Co.
9100 South Hills Boulevard
Broadview Heights, Ohio 44147-3518
Phone 1-440-262-1410 Revenue 1.05B
Industry Medical Specialties Net Income 51.09M
Sector Health Technology 2023 Sales Growth 4.543%
Fiscal Year-end 12 / 2024 Employees 3,000
View SEC Filings

SHC Valuation

P/E Current 53.586
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 93.404
Price to Sales Ratio 4.548
Price to Book Ratio 10.74
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 13.153
Enterprise Value to Sales 6.478
Total Debt to Enterprise Value 0.342

SHC Efficiency

Revenue/Employee 349,762.667
Income Per Employee 17,029.667
Receivables Turnover 5.978
Total Asset Turnover 0.336

SHC Liquidity

Current Ratio 2.416
Quick Ratio 2.191
Cash Ratio 1.308

SHC Profitability

Gross Margin 48.925
Operating Margin 33.973
Pretax Margin 10.105
Net Margin 4.869
Return on Assets 1.635
Return on Equity 12.869
Return on Total Capital 1.844
Return on Invested Capital 2.074

SHC Capital Structure

Total Debt to Total Equity 524.426
Total Debt to Total Capital 83.985
Total Debt to Total Assets 74.337
Long-Term Debt to Equity 520.031
Long-Term Debt to Total Capital 83.281
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Sotera Health Topco Inc - SHC

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
818.16M 931.48M 1.00B 1.05B
Sales Growth
+5.12% +13.85% +7.75% +4.54%
Cost of Goods Sold (COGS) incl D&A
433.62M 476.59M 509.62M 535.93M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
145.51M 153.15M 147.75M 160.34M
Depreciation
65.25M 66.41M 66.19M 78.99M
Amortization of Intangibles
80.25M 86.74M 81.55M 81.35M
COGS Growth
-1.78% +9.91% +6.93% +5.16%
Gross Income
384.54M 454.89M 494.06M 513.36M
Gross Income Growth
+14.15% +18.29% +8.61% +3.91%
Gross Profit Margin
+47.00% +48.84% +49.22% +48.92%
2020 2021 2022 2023 5-year trend
SG&A Expense
126.97M 154.48M 164.57M 156.88M
Research & Development
- - - -
-
Other SG&A
126.97M 154.48M 164.57M 156.88M
SGA Growth
-2.83% +21.67% +6.53% -4.67%
Other Operating Expense
- - - -
-
Unusual Expense
92.99M 61.98M 500.08M 113.15M
EBIT after Unusual Expense
164.58M 238.43M (170.59M) 243.33M
Non Operating Income/Expense
6.51M 12.66M 19.85M 16.53M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
209.95M 75.38M 92.37M 153.83M
Interest Expense Growth
+33.39% -64.10% +22.54% +66.54%
Gross Interest Expense
210.65M 76.48M 96.07M 166.03M
Interest Capitalized
700.00K 1.10M 3.70M 12.20M
Pretax Income
(38.86M) 175.72M (243.11M) 106.03M
Pretax Income Growth
-4,142.36% +552.18% -238.35% +143.61%
Pretax Margin
-4.75% +18.86% -24.22% +10.10%
Income Tax
(1.37M) 58.59M (9.54M) 54.65M
Income Tax - Current - Domestic
(10.39M) 17.14M 17.92M (2.88M)
Income Tax - Current - Foreign
32.38M 45.18M 46.50M 54.09M
Income Tax - Deferred - Domestic
(9.67M) (2.03M) (70.30M) 6.31M
Income Tax - Deferred - Foreign
(13.69M) (1.69M) (3.66M) (2.87M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - (1.52M) (287.00K)
-
Consolidated Net Income
(37.49M) 115.60M (233.57M) 51.09M
Minority Interest Expense
- - 1.13M 239.00K
-
Net Income
(38.62M) 115.36M (233.57M) 51.09M
Net Income Growth
-85.21% +398.72% -302.47% +121.87%
Net Margin Growth
-4.72% +12.38% -23.27% +4.87%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(38.62M) 115.36M (233.57M) 51.09M
Preferred Dividends
- - - -
-
Net Income Available to Common
(38.62M) 115.36M (233.57M) 51.09M
EPS (Basic)
-0.1363 0.4131 -0.8339 0.1818
EPS (Basic) Growth
-85.95% +403.08% -301.86% +121.80%
Basic Shares Outstanding
283.25M 279.23M 280.10M 281.01M
EPS (Diluted)
-0.1363 0.4129 -0.8339 0.1804
EPS (Diluted) Growth
-85.95% +402.93% -301.96% +121.63%
Diluted Shares Outstanding
283.25M 279.38M 280.10M 283.22M
EBITDA
403.08M 453.56M 477.25M 516.81M
EBITDA Growth
+13.56% +12.52% +5.22% +8.29%
EBITDA Margin
+49.27% +48.69% +47.55% +49.25%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 17.143
Number of Ratings 8 Current Quarters Estimate 0.204
FY Report Date 12 / 2024 Current Year's Estimate 0.694
Last Quarter’s Earnings 0.17 Median PE on CY Estimate N/A
Year Ago Earnings 0.81 Next Fiscal Year Estimate 0.79
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 6 8 8
Mean Estimate 0.20 0.14 0.69 0.79
High Estimates 0.22 0.15 0.71 0.83
Low Estimate 0.19 0.12 0.68 0.71
Coefficient of Variance 5.27 7.83 1.54 4.80

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 4
OVERWEIGHT 1 1 1
HOLD 3 3 3
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Sotera Health Topco Inc - SHC

Date Name Shares Transaction Value
Sep 13, 2024 Michael B. Petras Chairman & CEO 5,253,580 Bona fide gift 0.00
May 30, 2024 Vincent Kevin Petrella Director 61,649 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 30, 2024 David E. Wheadon Director 55,780 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 30, 2024 Karen A. Flynn Director 20,089 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 30, 2024 Ruoxi Chen Director 61,649 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 30, 2024 Ann R. Klee Director 106,824 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 30, 2024 Rob B. Knauss Director 35,801 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 30, 2024 James C. Neary Director 61,649 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 30, 2024 Sean Laurence Cunningham Director 61,649 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 30, 2024 Dean Spyro Mihas Director 61,649 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 30, 2024 Dave Anthony Donnini Director 61,649 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 7, 2024 Alexander Dimitrief SVP, General Counsel and Sec. 286,883 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 7, 2024 Alexander Dimitrief SVP, General Counsel and Sec. 102,095 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 7, 2024 GTCR LLC Director 59,215,301 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $14.31 per share 847,370,957.31
Mar 7, 2024 Jon Lyons Sr. Vice President, CFO 118,091 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 7, 2024 Jon Lyons Sr. Vice President, CFO 81,676 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 7, 2024 Warburg Pincus LLC Director 88,822,952 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $14.31 per share 1,271,056,443.12
Mar 6, 2024 Michael B. Petras Chairman & CEO 425,589 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $14.56 per share 6,196,575.84
Mar 6, 2024 Michael B. Petras Chairman & CEO 699,749 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2024 Michael B. Petras Chairman & CEO 5,453,580 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $14.31 per share 78,040,729.80

Sotera Health Topco Inc in the News